Literature DB >> 22551023

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

Stephen E Goldstone1, Scott Vuocolo.   

Abstract

Human papillomavirus infection causes cervical cancer, a significant portion of anal, genital and oropharyngeal cancers, genital warts and recurrent respiratory papillomatosis. In June 2006, a quadrivalent human papillomavirus-6/11/16/18 vaccine (GARDASIL/SILGARD®; Merck, NJ, USA) was licensed in the USA; subsequent approval has been granted in the EU (September 2006). It has since been approved in 121 countries with over 74 million doses distributed globally as of March 2011.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22551023     DOI： 10.1586/erv.12.20

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  4 in total

1.  Human Papillomavirus Vaccination and Infection in Young Sexual Minority Men: The P18 Cohort Study.

Authors:  Perry N Halkitis; Pamela Valera; Caleb E LoSchiavo; Stephen E Goldstone; Maria Kanztanou; Anthony J Maiolatesi; Danielle C Ompad; Richard E Greene; Farzana Kapadia
Journal:  AIDS Patient Care STDS       Date:  2019-04       Impact factor: 5.078

Review 2.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

3.  Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

Authors:  Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

4.  Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).

Authors:  Macey L Murray; Jade Meadows; Caroline J Doré; Andrew J Copas; Lewis J Haddow; Charles Lacey; Mark Jit; Kate Soldan; Kate Bennett; Michelle Tetlow; Mayura Nathan; Richard Gilson
Journal:  BMC Med Res Methodol       Date:  2018-11-06       Impact factor: 4.615
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.